Argenx (ARGX)
(Delayed Data from NSDQ)
$371.02 USD
+8.86 (2.45%)
Updated May 31, 2024 04:00 PM ET
After-Market: $371.31 +0.29 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 121 - 140 ( 279 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
argenx Goes Global With Second MG Approval for Efgartigimod, This Time in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Happy Holidays for argenx and MG Patients Indeed: FDA Approves Efgartigimod (Vyvgart) with Broad Label
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation with argenx CEO: Lots to Look Forward to Beyond Efgartigimod Launch in MG; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Final Countdown to Efgartigimod Commercialization as Regulatory Decisions Near
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Efgartigimod Priming for T Minus Zero With All Cylinders Firing
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
In our 7th installment of HCW @ Home, we are pleased to host argenx CEO,
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Quiet 2Q Report After Analyst Day Reveals; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D